ATAI Life Sciences (ATAI) AI Stock Analysis

• Market Cap: $1.51B
• Dividend Yield: N/A
• Average Volume (3M): 7.03M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.35
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: US
• Employees: 54
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.14
• Shares Outstanding: 261,063,140
• 10 Day Avg. Volume: 9,218,400
• 30 Day Avg. Volume: 7,033,322
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 0.23
• Enterprise Value/Revenue: 148.95
• Enterprise Value/Gross Profit: 148.95
• Enterprise Value/Ebitda: -2.97
• 1Y Price Target: $12.71
• Price Target Upside: 120.28% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 8

• Rating: 54 Neutral
• Price Target: $6.00 ▲(3.99% Upside)

ATAI Life Sciences' overall stock score is primarily impacted by its poor financial performance, characterized by ongoing losses and negative cash flows. The technical analysis provides some positive momentum, but the valuation remains unattractive due to a negative P/E ratio and lack of dividend yield. The absence of earnings call data and corporate events limits additional insights.

Positive Factors

Strategic Acquisitions

The acquisition of Beckley Psytech aims to create a market leader in psychedelic mental health therapies, enhancing ATAI's competitive position and accelerating its development pipeline.

Financing Agreement

The $50M PIPE financing supports ATAI's operations and clinical programs, providing financial stability and enabling continued investment in its therapeutic pipeline.

Pipeline Development

Positive Phase IIb results for BPL-003 in treatment-resistant depression support advancing to Phase III, indicating strong potential for future product offerings and market expansion.

Negative Factors

Negative Cash Flows

Persistent negative cash flows highlight inefficiencies in cash management and reliance on external financing, posing risks to long-term operational sustainability.

Profitability Challenges

Ongoing profitability challenges with negative earnings indicate significant cost pressures and difficulty in generating revenue, impacting long-term financial health.

Revenue Growth Issues

Lack of revenue growth highlights challenges in market penetration and product adoption, potentially limiting future financial performance and competitive positioning.

ATAI Life Sciences Business Overview & Revenue Model

Company Description

ATAI Life Sciences is a biotechnology company focused on the development of innovative treatments for mental health disorders. Operating in the life sciences sector, ATAI aims to transform the mental health landscape by leveraging advanced therapeutics and psychedelic compounds. The company collaborates with various entities to create a diverse pipeline of products, including novel therapies for conditions such as depression, anxiety, and addiction.

How the Company Makes Money

ATAI Life Sciences generates revenue primarily through the development and commercialization of its therapeutic products. The company partners with pharmaceutical firms, research institutions, and other stakeholders to co-develop its drug candidates, which can lead to milestone payments and royalties upon successful commercialization. Additionally, ATAI may receive funding from grants or investments aimed at supporting its research initiatives. Strategic partnerships with larger pharmaceutical companies can also provide substantial financial backing, facilitating further research and development while sharing potential profits from successful product launches.

ATAI Life Sciences Financial Statement Overview

Summary

ATAI Life Sciences faces significant financial challenges, marked by ongoing losses and lack of revenue growth. Despite a low leverage position, negative cash flows and earnings pose substantial risks. Financial sustainability relies heavily on external funding.

Income Statement

ATAI Life Sciences has consistently faced challenges with profitability, as indicated by negative EBIT and net income figures across all reported years. The absence of revenue growth further underscores the company's struggle to generate revenue. The gross profit remained negative or negligible, pointing towards significant cost pressures and lack of revenue generation capabilities.

Balance Sheet

The company's balance sheet shows a high level of equity in comparison to its total assets, with an improving trend in stockholders' equity, despite negative earnings. The debt-to-equity ratio is relatively low, suggesting conservative leverage use. However, the continued accumulation of losses poses a risk to financial stability over time.

Cash Flow

ATAI Life Sciences has struggled to generate positive cash flows, with negative operating and free cash flows reported consistently. The cash flow to net income ratios indicate inefficiencies in cash management. The company's ability to sustain operations heavily depends on external financing, evident from periodic positive financing cash flows.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	2.31M	308.00K	314.00K	233.00K	20.38M	0.00
Gross Profit	2.31M	308.00K	314.00K	65.00K	20.33M	-24.00K
EBITDA	-115.81M	-145.33M	-36.31M	-135.01M	-120.28M	-92.12M
Net Income	-119.40M	-149.27M	-40.22M	-141.41M	-132.61M	-102.12M
Balance Sheet
Total Assets	189.20M	159.39M	293.48M	305.44M	414.17M	111.55M
Cash, Cash Equivalents and Short-Term Investments	95.94M	62.33M	179.26M	273.11M	362.27M	97.25M
Total Debt	9.22M	24.71M	19.14M	15.12M	743.00K	2.18M
Total Liabilities	45.28M	42.83M	49.16M	300.42M	28.21M	16.18M
Stockholders Equity	143.74M	116.30M	242.96M	260.74M	376.91M	90.82M
Cash Flow
Free Cash Flow	-80.79M	-82.53M	-84.71M	-105.49M	-64.37M	-20.82M
Operating Cash Flow	-75.57M	-82.44M	-84.12M	-104.47M	-63.25M	-20.77M
Investing Cash Flow	30.17M	59.17M	-53.30M	-86.85M	-81.28M	-28.27M
Financing Cash Flow	72.41M	5.37M	-8.36M	20.79M	409.86M	113.05M

ATAI Life Sciences Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 5.77
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ATAI, the sentiment is Positive. The current price of 5.77 is above the 20-day moving average (MA) of 5.60, above the 50-day MA of 5.04, and above the 200-day MA of 2.83, indicating a bullish trend. The MACD of 0.25 indicates Positive momentum. The RSI at 54.70 is Neutral, neither overbought nor oversold. The STOCH value of 31.27 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ATAI.

ATAI Life Sciences Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CVAC	74 Outperform	$1.21B	5.90	―	―	799.36%	―
PRAX	58 Neutral	$4.21B	-14.16	-60.98%	―	338.45%	-19.64%
ATAI	54 Neutral	$1.51B	―	―	―	―	―
NKTR	54 Neutral	$1.14B	―	-440.80%	―	-19.56%	35.55%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
WVE	43 Neutral	$1.12B	―	-171.41%	―	-14.98%	-51.76%
ORIC	43 Neutral	$1.21B	―	-43.82%	―	―	-7.33%

ATAI Life Sciences Corporate Events

ATAI Life Sciences Closes $149.5 Million Public Offering

On October 20, 2025, atai Life Sciences announced the successful closing of its public offering of 27,283,750 common shares, raising approximately $149.5 million. The proceeds, along with existing cash resources, will fund the advancement of clinical trials for its product candidates, including the Phase 3 program for BPL-003 and Phase 2 trials for VLS-01 and EMP-01. This financing is expected to support operations into 2029, reflecting strong investor confidence in atai’s mission to transform mental health treatment.

The most recent analyst rating on (ATAI) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on ATAI Life Sciences stock, see the ATAI Stock Forecast page.

ATAI Life Sciences’ BPL-003 Receives FDA Breakthrough Designation

On October 16, 2025, atai Life Sciences and Beckley Psytech announced that the U.S. FDA granted Breakthrough Therapy designation to BPL-003, an intranasal formulation for treatment-resistant depression. This designation, following positive Phase 2b trial results, highlights BPL-003’s potential to significantly improve depressive symptoms rapidly and durably, fitting into existing treatment paradigms. The designation is expected to expedite the development and regulatory review process, positioning BPL-003 for Phase 3 trials in 2026, and underscores the potential impact on patients and the mental health treatment landscape.

The most recent analyst rating on (ATAI) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on ATAI Life Sciences stock, see the ATAI Stock Forecast page.

ATAI Life Sciences to Acquire Beckley Psytech

ATAI Life Sciences N.V. has announced a share purchase agreement dated June 2, 2025, to acquire the remaining issued share capital of Beckley Psytech Limited, a company based in England and Wales. The transaction is expected to close in the fourth quarter of 2025, pending shareholder approval and other conditions. This acquisition could potentially enhance ATAI’s position in the mental health treatment industry, although there are risks related to the completion and benefits realization of the transaction.

The most recent analyst rating on (ATAI) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on ATAI Life Sciences stock, see the ATAI Stock Forecast page.

ATAI Life Sciences to Acquire Beckley Psytech Shares

ATAI Life Sciences announced a share purchase agreement dated June 2, 2025, to acquire the remaining shares of Beckley Psytech Limited, a company based in England and Wales. The transaction is expected to close in the fourth quarter of 2025, pending shareholder approval and other customary conditions, potentially impacting ATAI’s market position and operational capabilities.

The most recent analyst rating on (ATAI) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on ATAI Life Sciences stock, see the ATAI Stock Forecast page.

ATAI Life Sciences Announces Positive Phase 2a Study Results

On September 23, 2025, ATAI Life Sciences and Beckley Psytech announced positive results from a Phase 2a study of BPL-003, an intranasal formulation for treatment-resistant depression. The study demonstrated that a two-dose regimen of BPL-003 led to significant reductions in depression scores and improved remission rates, with sustained effects and a strong safety profile. These findings support further development and regulatory discussions for Phase 3 trials, potentially enhancing ATAI’s position in the mental health treatment industry.

The most recent analyst rating on (ATAI) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on ATAI Life Sciences stock, see the ATAI Stock Forecast page.

Atai Life Sciences Reports Q2 2025 Financial Results

Atai Life Sciences N.V. is a clinical-stage biopharmaceutical company focused on developing innovative treatments for mental health disorders, leveraging both psychedelic and non-psychedelic compounds. The company recently released its earnings report for the quarter ending June 30, 2025, highlighting its ongoing efforts in advancing its diverse pipeline of psychiatric product candidates.